WallStSmart
NTBL

Notable Labs Inc.

NASDAQ: NTBL · HEALTHCARE · BIOTECHNOLOGY

$0.25
+0.00% today

Updated 2026-05-01

Market cap
$2.39M
P/E ratio
P/S ratio
7.65x
EPS (TTM)
$-1.09
Dividend yield
52W range
$0 – $0
Volume
2.1M

Notable Labs Inc. (NTBL) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for NTBL.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 27 / 100
P/E (TTM)
Not meaningful for this profile
PEG
Margin of Safety
-77.07%
Fair value $0.14 vs $0.25
EV / EBITDA
0.0x

NTBL historical valuation range

Where current P/E sits in NTBL's own 5Y range.

Insufficient historical data for 5Y percentile analysis

NTBL intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

Current price
$0.25
Market value
Intrinsic value
$0.14
DCF estimate
Margin of safety
-77.07%
-43.5% upside to fair value

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

NTBL valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

Premium to fair value
Price exceeds DCF intrinsic value by 77.1%. Limited downside protection.
Weak financial quality
Piotroski F-Score of 0/9 suggests deteriorating fundamentals. Valuation requires closer scrutiny.

P/E Ratio — History

No historical P/E data available

P/S Ratio — History

Current: 7.65x

Is NTBL overvalued in 2026?

Notable Labs Inc. (NTBL) currently trades at $0.25 per share with a market capitalization of $2,394,600.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 27/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

NTBL currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 7.7x, the market is valuing the company primarily on its revenue rather than its earnings.

Our discounted cash flow model estimates NTBL's intrinsic value at $0.14 per share, against the current market price of $0.25. This implies a premium to fair value of -77.07%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.

Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.

Bottom line: NTBL appears richly valued on our framework, with a Smart Value Score of 27/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is NTBL overvalued in 2026?

Based on a Smart Value Score of 27/100, NTBL appears overvalued. Current price exceeds what fundamentals currently justify.

What is NTBL's fair value?

Our DCF model estimates NTBL's intrinsic value at $0.14 per share, versus the current price of $0.25. This produces a margin of safety of -77.07%.

What P/E ratio does NTBL trade at?

NTBL does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.

Is NTBL a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 27/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does NTBL's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on NTBL.

What is NTBL's Smart Value Score?

NTBL's Smart Value Score is 27/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.